Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of BRCA1 or BRCA2 Mutations

We hypothesized that cells bearing a single inherited “hit” in a tumor suppressor gene express an altered mRNA repertoire that may identify targets for measures that could delay or even prevent progression to carcinoma. We report here on the transcriptomes of primary breast and ovarian epithelial cells cultured from BRCA1 and BRCA2 mutation carriers and controls. Our comparison analyses identified multiple changes in gene expression, in both tissues for both mutations, which were validated independently by real-time reverse transcription-PCR analysis. Several of the differentially expressed genes had been previously proposed as cancer markers, including mammaglobin in breast cancer and serum amyloid in ovarian cancer. These findings show that heterozygosity for a mutant tumor suppressor gene can alter the expression profiles of phenotypically normal epithelial cells in a gene-specific manner; these detectable effects of “one hit” represent early molecular changes in tumorigenesis that may serve as novel biomarkers of cancer risk and as targets for chemoprevention. Cancer Prev Res; 3(1); 48–61

[1]  L. Kopelovich.  Genetic predisposition to cancer in man: in vitro studies. , 1982, International review of cytology.

[2]  J Wade Harper,et al.  The DNA damage response: ten years after. , 2007, Molecular cell.

[3]  L. Kopelovich.  Phenotypic markers in human skin fibroblasts as possible diagnostic indices of hereditary adenomatosis of the colon and rectum , 1977, Cancer.

[4]  Raymond N DuBois,et al.  Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. , 2003, Cancer research.

[5]  L. Erickson.  The role of O-6 methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibition. , 1991, Seminars in cancer biology.

[6]  B. Danes.  Increased in vitro tetraploidy: Tissue specific within the heritable colorectal cancer syndromes with polyposis coli , 1978, Cancer.

[7]  S. Lo,et al.  Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer. , 2002, Cancer research.

[8]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[9]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[10]  J. Morrow,et al.  Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. , 2005, Cancer research.

[11]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[12]  M. Campa,et al.  Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma , 2004, Cancer.

[13]  M. King,et al.  Insights into the functions of BRCA1 and BRCA2. , 2000, Trends in genetics : TIG.

[14]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[15]  Mark A Watson,et al.  Identification of Mammaglobin as a Novel Serum Marker for Breast Cancer , 2005, Clinical Cancer Research.

[16]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[17]  K. Devarajan,et al.  Comparison of RNA amplification methods and chip platforms for microarray analysis of samples processed by laser capture microdissection , 2008, Journal of cellular biochemistry.

[18]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[19]  L. Kopelovich.  Heritable colorectal cancer and cancer genes: Systemic expressions , 1993, Molecular carcinogenesis.

[20]  Xuchen Cao,et al.  Expression level of insulin‐like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer , 2007, Cancer science.

[21]  S. Merajver,et al.  BRCA1 regulates human mammary stem/progenitor cell fate , 2008, Proceedings of the National Academy of Sciences.

[22]  Victor G Zgoda,et al.  Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1 , 2005, Proteomics.

[23]  P. Kristjansen,et al.  Regulation of YKL‐40 expression during genotoxic or microenvironmental stress in human glioblastoma cells , 2005, Cancer science.

[24]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[25]  Bernard T. Lee,et al.  Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. , 2009, Cancer research.

[26]  Gavin Sherlock,et al.  Isolation and Molecular Characterization of Cancer Stem Cells in MMTV‐Wnt‐1 Murine Breast Tumors , 2008, Stem cells.

[27]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[28]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[29]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[30]  A. Knudson,et al.  Endogenous DNA double-strand breaks: Production, fidelity of repair, and induction of cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Berchuck,et al.  Matrix Metalloproteinase-1 Gene Promoter Polymorphism and Risk of Ovarian Cancer , 2003, The Journal of the Society for Gynecologic Investigation: JSGI.

[32]  D. Mavroudis,et al.  Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. , 2006, Clinical biochemistry.

[33]  Bhavinkumar B. Patel,et al.  One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. , 2008, Cancer research.

[34]  Yoshio Miki,et al.  Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage , 2004, Cancer science.

[35]  P. Kenemans,et al.  Human MUC1 Mucin: A Multifaceted Glycoprotein , 2000, The International journal of biological markers.

[36]  P. Armitage,et al.  The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.

[37]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Lengyel,et al.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. , 2008, The Journal of clinical investigation.

[39]  Jae K. Lee,et al.  Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays , 2003, Bioinform..

[40]  H. Riele,et al.  Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level , 2002, Oncogene.

[41]  Francisco Tirado,et al.  bioNMF: a versatile tool for non-negative matrix factorization in biology , 2006, BMC Bioinformatics.

[42]  C. Shaw,et al.  Transcriptional Profiling of Mammary Gland Side Population Cells , 2006, Stem cells.

[43]  A. Iwamatsu,et al.  Ubiquitin‐immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer , 2003, Cancer science.

[44]  James D Iglehart,et al.  Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. , 2007, Cancer cell.

[45]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[46]  A. Knudson,et al.  Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations , 2004, Cancer biology & therapy.